OncoAlert ✓

@OncoAlert · Worldwide · joined 22 Mar 2019

🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°

42 471Followers

138Following

124 953Posts total

22.8KViews on collected posts

Son gönderiler

OncoAlert ✓@OncoAlert18 Sep

@OncoAlert Such exciting times to treat this terrible disease. 7 views · 0 likes · 0 reposts · 0 replies Open on X →

OncoAlert ✓@OncoAlert17 Sep

@OncoAlert Kudos to the trial teams and patients who enrolled. 58% ORR with a complete response in 1L metastatic PDAC is extraordinary. I'll be watching RAsolute 303 closely. Will be interesting to see if it holds up. 12 views · 1 likes · 0 reposts · 0 replies Open on X →

OncoAlert ✓@OncoAlert15 Sep

FDA News📰 : daraxonrasib in hashtag#PancreaticCancer Source: Revolution Medicines The FDA 🇺🇸 recently granted Breakthrough Therapy Designation to Revolution Medicines' RASONQUE (daraxonrasib) combined with gemcitabine/nab-paclitaxel for treatment-naïve metastatic pancreatic http

2.3K views · 22 likes · 15 reposts · 2 replies Open on X →

OncoAlert ✓@OncoAlert14 Sep

@OncoAlert I'm curious to see how it compares to other therapies currently available. 10 views · 0 likes · 0 reposts · 0 replies Open on X →

OncoAlert ✓@OncoAlert14 Sep

@OncoAlert The clinical benefit raises important questions about whether B7-H3 expression, tumor heterogeneity, or other biomarkers 🎯could help identify which patients are most likely to benefit from this ADC. 77 views · 5 likes · 0 reposts · 0 replies Open on X →

OncoAlert ✓@OncoAlert14 Sep

🚨 Could B7-H3 targeting represent a meaningful new direction in relapsed small-cell lung cancer? #WCLC26 👉 NEJM Article https://t.co/emwFFSogDi Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy In a phase 3 randomized trial of 451 patients with htt

2.3K views · 17 likes · 11 reposts · 2 replies Open on X →

OncoAlert ✓@OncoAlert9 Sep

🚨 OncoAlert HORIZONS | HER2+ Breast Cancer 🎯 Educational Series | Early HER2+ Breast Cancer: Escalate, De-escalate, or Personalise? What does the future of personalised treatment look like for patients with early HER2+ breast cancer? In this new OncoAlert HORIZONS https://t.co

19:41

399 views · 6 likes · 2 reposts · 0 replies Open on X →

OncoAlert ✓@OncoAlert9 Sep

📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow 📅 November 11–13, 2026 (NY, NY🇺🇸 ) REGISTER 👉 https://t.co/ktC7JSRuZB HYBRID MEETING (Online and In Person) 🚨 FREE🆓 REGISTRATION with Code: OncoAlert For more https:/

0:47

321 views · 3 likes · 0 reposts · 0 replies Open on X →

OncoAlert ✓@OncoAlert9 Sep

When metastatic breast cancer progresses in just a few sites, should we change the systemic therapy—or treat the resistant sites and stay the course? 🎯 https://t.co/Gfu9iAulm1 Does stereotactic☢️ ablative body radiotherapy (SABR) added to continued systemic therapy improve ht

561 views · 18 likes · 10 reposts · 0 replies Open on X →

OncoAlert ✓@OncoAlert8 Sep

NEWS from Industry: DeLLphi-305 Update in Small Cell Lung Cancer Source: Amgen The Phase 3 DeLLphi-305 study showed a statistically significant and clinically meaningful overall survival benefit for tarlatamab-dlle plus Imfinzi durvalumab 🆚 durvalumab alone as first-line https

9.5K views · 14 likes · 7 reposts · 0 replies Open on X →

OncoAlert ✓@OncoAlert8 Sep

AcuVox 🚨 is LIVE ANRE READY Visit us👉 https://t.co/1STxKSU7zh Oncology moves fast. The signal moves faster. AcuVox turns the noise from major congresses into real-time intelligence — the trials, data, and Colleague insights that actually matter. Most importantly... IT'S FREE h

1.5K views · 13 likes · 6 reposts · 0 replies Open on X →

OncoAlert ✓@OncoAlert2 Jun

Dear Colleagues at #ASCO26 A great way to end this final day of the meeting that with a presentation straight from the Podium to your feed. @OncoAlert proudly presents Dr. Roger Von Moos 🇨🇭who just presented Abs 1004 at ASCO: Prevalence of symptomatic skeletal events (SSE) htt

2:41

5.7K views · 20 likes · 16 reposts · 0 replies Open on X →

Aynı büyüklükteki hesaplara karşı

Son 90 güne ait 11 gönderi, 10K–100K takipçi aralığıyla yan yana. aynı büyüklükteki hesaplardan daha az kişiye ulaşıyor.

Medyan görüntülenme399bu hesap92410K–100K için medyan

Erişim, %0.94%bu hesap3.62%10K–100K için medyan

Etkileşim, %1.33%bu hesap1.52%10K–100K için medyan

Ölçüt	Bu hesap	10K–100K için medyan	Oran
Gönderi başına medyan görüntülenme	399	924	0.43×
Erişim (görüntülenme ÷ takipçi)	0.94%	3.62%	0.26×
Etkileşim oranı	1.33%	1.52%	0.87×

Bu aralıktaki diğer hesaplar → Başka bir hesapla karşılaştır → Bu kıyas değerleri nasıl kuruluyor →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

5.7K2 Jun

1.5K8 Sep

9.5K

5619 Sep

321

399

2.3K14 Sep

2.3K15 Sep

1217 Sep

718 Sep

Last 12 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.66%2 Jun

1.30%8 Sep

0.27%

4.99%9 Sep

0.93%

2.01%

1.33%14 Sep

6.49%

0.00%

1.72%15 Sep

8.33%17 Sep

0.00%18 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes57.8%119 in total

Reposts32.5%67 in total

Replies1.9%4 in total

Quotes4.4%9 in total

Bookmarks3.4%7 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Son gönderiler

Aynı büyüklükteki hesaplara karşı

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Benzer hesaplar